You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ONZETRA XSAIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Onzetra Xsail, and what generic alternatives are available?

Onzetra Xsail is a drug marketed by Currax and is included in one NDA. There are sixteen patents protecting this drug.

This drug has two hundred and sixty-six patent family members in twenty-nine countries.

The generic ingredient in ONZETRA XSAIL is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Onzetra Xsail

A generic version of ONZETRA XSAIL was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ONZETRA XSAIL?
  • What are the global sales for ONZETRA XSAIL?
  • What is Average Wholesale Price for ONZETRA XSAIL?
Summary for ONZETRA XSAIL
International Patents:266
US Patents:16
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 115
Clinical Trials: 1
Patent Applications: 2,223
Drug Prices: Drug price information for ONZETRA XSAIL
What excipients (inactive ingredients) are in ONZETRA XSAIL?ONZETRA XSAIL excipients list
DailyMed Link:ONZETRA XSAIL at DailyMed
Drug patent expirations by year for ONZETRA XSAIL
Drug Prices for ONZETRA XSAIL

See drug prices for ONZETRA XSAIL

Recent Clinical Trials for ONZETRA XSAIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Currax PharmaceuticalsPhase 3
Avanir PharmaceuticalsPhase 3

See all ONZETRA XSAIL clinical trials

US Patents and Regulatory Information for ONZETRA XSAIL

ONZETRA XSAIL is protected by twenty-two US patents.

Patents protecting ONZETRA XSAIL

Nasal delivery devices
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nasal delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY

Nasal delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE

Nasal delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY

Nasal delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE

Nasal delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE

Nasal delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY

Nasal delivery devices
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nasal administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY

Nasal administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Nasal devices
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Nasal delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nasal delivery devices
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Nasal administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY

Powder delivery devices
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nasal delivery
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nasal delivery devices
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nasal delivery device
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Nasal administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE

Nasal administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY

Nasal administration
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ONZETRA XSAIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 ⤷  Sign Up ⤷  Sign Up
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 ⤷  Sign Up ⤷  Sign Up
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 ⤷  Sign Up ⤷  Sign Up
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 ⤷  Sign Up ⤷  Sign Up
Currax ONZETRA XSAIL sumatriptan succinate POWDER;NASAL 206099-001 Jan 27, 2016 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ONZETRA XSAIL

See the table below for patents covering ONZETRA XSAIL around the world.

Country Patent Number Title Estimated Expiration
China 1736502 ⤷  Sign Up
Denmark 1555038 ⤷  Sign Up
Brazil 0210332 ⤷  Sign Up
Russian Federation 2258538 НОСОВОЕ ПОДАЮЩЕЕ УСТРОЙСТВО (FEEDING APPARATUS FOR NOSE) ⤷  Sign Up
Canada 2598953 DISPOSITIFS D'ADMINISTRATION DE POUDRE (NASAL DELIVERY DEVICE) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.